For instance, the small-molecule inhibitor AMD3100, the peptide-based inhibitors BL-8040 and LY2510924, and anti-CXCR4 monoclonal antibodies have been used in several clinical trials for patients with acute myeloid leukemia (AML) and ALL, both as monotherapies and in combination with chemotherapy (as reviewed in [22]). Here, CXCR4 is linked to acute lymphoblastic leukemia.